Human Regular U‐500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with Type 2 Diabetes: the VIVID Study

AIM: To compare the safety and efficacy of U500-R delivered by a novel, specifically designed U500-R insulin pump with U-500R delivered by multiple daily injections (MDI). METHODS: The phase 3 VIVID study randomized people with type 2 diabetes to U-500R by continuous subcutaneous insulin infusion (CSII) or MDI. Participants (aged 18-85 years) had HbA1c >/=7.5% and 200 and